The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Tetra Bio-Pharma’s investigational cannabinoid cream PPP004 (THC-CBD)…
Articles by Patricia Inácio, PhD
Family members caring for children with epidermolysis bullosa (EB) report considerable stress, fatigue and feelings of helplessness, and need…
The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However,…
Cannabinol (CBN), a rare type of cannabinoid, is the active component of InMed Pharmaceuticals‘ INM-755 treatment candidate…
Castle Creek Pharmaceutical recently acquired Fibrocell Science and is now leading the development of treatments for epidermolysis bullosa…
The Epidermolysis Bullosa iPS Cell Consortium has received $1.6 million in funding to develop stem cell-based therapies for people…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to APR-TD011, a spray therapy candidate for the…
Taking multiple precautions can ensure that pregnancy, delivery, and the postpartum period are uncomplicated in women with epidermolysis bullosa…
Note: This story has been updated to note that the gene that codes for collagen type VII protein is the…
The topical gene therapy candidate KB103 to treat dystrophic epidermolysis bullosa (DEB) has been granted PRIME (PRIority MEdicines) designation…
Note: This story has been updated to note that the gene that codes for collagen type VII protein is the…
Next-generation sequencing — a technique that reads DNA sequences much faster and cheaper than standard approaches — successfully identified a novel…